SPY420.86+5.94 1.43%
DIA338.78+5.82 1.75%
IXIC14,141.48+111.10 0.79%

HC Wainwright & Co. Maintains Buy on Celyad Oncology, Lowers Price Target to $17

HC Wainwright & Co. analyst Edward White maintains Celyad Oncology (NASDAQ:CYAD) with a Buy and lowers the price target from $18 to $17.

05/10/2021 06:12
HC Wainwright & Co. analyst Edward White maintains Celyad Oncology (NASDAQ:CYAD) with a Buy and lowers the price target from $18 to $17.